Evidence Grade C — Moderate human evidence. 61 published studies, 21 human. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Epitalon is the most studied peptide in the Khavinson bioregulator programme from Russia — a synthetic tetrapeptide investigated for effects on telomerase (the enzyme that maintains chromosome protective caps) and lifespan in animal models. It has no approval from any major regulatory agency, and no controlled human clinical trials have been conducted.
Epitalon is also known by these brand and alternate names:
61 published studies: 21 human, 36 animal, 9 in-vitro, 7 reviews
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base.
The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Epitalon may activate telomerase through effects on hTERT gene expression. Studies in cell culture have reported telomere elongation and telomerase activation. These observations are from in vitro and animal experiments published primarily by the originating research group and have not been independently replicated.
Research from the Khavinson group reports that Epitalon activated telomerase in cell cultures and extended lifespan in mice. These findings span decades and show a consistent direction, but the vast majority originate from a single research group. Recent independent work (2025) has begun to provide external validation of the telomerase mechanism. A paradox exists: telomerase activation is generally associated with cancer risk (cancer cells use telomerase to become immortal), yet the animal studies report reduced tumour incidence — a finding that remains unexplained. No properly controlled human trials, no formal pharmacokinetic data, and no independent replication of the lifespan claims exist. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Epitalon sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Epitalon (also spelled Epithalon or Epithalone) is the most extensively studied Khavinson peptide, representing the synthetic active component of Epithalamin (bovine pineal gland extract). Its sequence is Ala-Glu-Asp-Gly (AEDG), with molecular formula C14H22N4O9 and molecular weight 390.35 Da (CAS: 307297-39-8; PubChem CID: 219042; UNII: O65P17785G). Available as a white lyophilized powder that is water-soluble. Research administration routes include subcutaneous injection, intraperitoneal injection, and intranasal. The modified form N-Acetyl Epithalon Amidate (MW 446.45 Da) is also commercially available with enhanced stability. Not approved by any Western regulatory agency.
Research suggests Epitalon's primary mechanism involves telomerase activation through hTERT expression. Khavinson et al. (2003) demonstrated that Epitalon induced telomerase activity in previously telomerase-negative human fetal fibroblasts, producing average telomere elongation of approximately 33.3%. Treated fibroblasts continued dividing past the 44th passage versus controls stopping at the 34th, a 42.5% increase in cellular divisions beyond the Hayflick limit. A 2025 study (Al-dulaimi et al., Biogerontology) confirmed dose-dependent telomere extension with 12-fold hTERT upregulation at 1 ug/mL in 21NT cells and 5-fold in BT474 cells. Research suggests Epitalon restores melatonin secretion in aged organisms, suppresses aging biomarkers CCL11 (eotaxin) and HMGB1, regulates the PER1 clock gene, and inhibits MMP9 in aging fibroblasts. Epitalon is reported effective at 1,000-5,000x lower concentrations than the crude Epithalamin extract.
Animal lifespan studies form the core evidence. Anisimov et al. (2003; n=54/group, female SHR mice) showed no change in mean lifespan but +12.3% maximum lifespan, with chromosomal aberrations reduced 17.1% (p < 0.05). Anisimov and Khavinson (2010; female CBA mice) showed +42% maximum lifespan, +5% mean lifespan, and 4x more mice surviving to 24 months versus controls. In HER-2/neu transgenic mice, mammary carcinogenesis was inhibited with HER-2/neu mRNA reduced 3.7-fold. In Drosophila, mean lifespan increased 11-16%. Human data (all from Khavinson's group) includes a prospective cohort (N=266, age >60, 6-year follow-up) where Epithalamin reduced mortality 1.6-1.8x; combined with Thymalin, mortality reduction was 4.1x with annual administration. A coronary patient study (N=79, >12-year follow-up) showed biannual epithalamin treatments produced 50% lower cardiovascular mortality and 28% lower overall mortality. In retinitis pigmentosa, positive clinical effect was reported in 90% of treated cases.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 41 vendor listings
View pricing data across vendors and countries for Epitalon
GHK has no pharmaceutical authorisation. Small cosmetic studies of the copper-complexed form (GHK-Cu) have reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable use have been completed. As with GHK-Cu (#85), the cosmetic evidence base for topical use should be distinguished from claims about injectable use. Gene expression profiling studies have reported broad effects, but observational genomic changes do not constitute evidence of therapeutic efficacy. This entry overlaps substantially with GHK-Cu (#85).
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application. The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
